AX-202
- Generic Name
- AX-202
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
Phase 1
Completed
- Conditions
- Mild to Moderate PsoriasisHealthy Volunteers
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Arxx Therapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT05965089
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, Wythenshawe, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath